In this Clinical Issues™ live symposium, an expert faculty panel will discuss and debate the latest insights into RA immunopathology with a focus on JAK enzyme activation, increase their understanding of treat-to-target recommendations and appropriate disease activity measures, and describe the mechanistic profiles and clinical trial data for current and emerging targeted synthetic DMARDs. Attendees will leave this engaging program with new information and a fresh perspective on the evolving best practices for managing patients with RA.
Elsevier's Office of Continuing Medical Education offers the most comprehensive list of primary care CME courses. Check out the list below to ramp up on the latest topics in primary care.
Evolving Treatment Paradigms for Rheumatoid Arthritis: Translating Comprehensive Patient Evaluations Into Personalized TherapyFormat: Webcast Series
Welcome to this RA CME Snapshot™ video series. Each 15-minute module offers focused, clinically actionable education for rheumatologists and other clinicians who manage patients with RA. For a comprehensive curriculum on current evidence-based guidelines and newly published data on the use of targeted inhibitors of interleukin (IL)-6 or Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathways, clinicians can complete all 6 video modules for a total of 1.5 AMA PRA Category 1 Credits™ or 1.5 hours of nursing contact hours.
Breathing Life Into COPD Management: Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized CareFormat: Webcast Series
This CME-accredited CME Snapshot™ educational series, Breathing Life Into COPD Management: Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care is intended for primary care clinicians and other health care providers involved in the ongoing management of patients with chronic obstructive pulmonary disease (COPD). Within each focused activity, an expert pulmonologist and a primary care educator discuss best practices for a specific aspect of managing patients with COPD, including monitoring the disease course over time, maximizing patient function, and individualizing treatment regimens. One activity also addresses patients’ perspectives by incorporating patient-clinician interactions and insights into disease burdens, challenges to good long-term outcomes, and shared decision-making.
The AAT-AD/PD™ Focus Meeting 2018 was held in Turin, Italy, March 15-18, 2018. During the new joint meeting between the International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) and AD/PD,TM the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development, and clinical trials in Alzheimer's, Parkinson's, and other related neurological disorders were at the forefront of the meeting. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on AD.
Evolving Paradigms for Managing Prostate Cancer: Implementing Multimodal Therapy in the Community SettingFormat: Webcast
Over the past 13 years, several new agents have been approved to treat patients with metastatic prostate cancer (PC). As a result, clinical guidelines have been updated frequently that support the expanding the role of combination therapy, particularly by introducing chemotherapy earlier to patients with castrate-sensitive progressive disease. Community urologists often treat PC patients many years before the development of progressive disease, and a growing number of urologists have successfully implemented advanced prostate cancer clinics (APCCs) within their practice setting in order to do so. This interactive activity will discuss the benefits of creating an APCC as well as all of the infrastructure requirements and practical considerations for administering chemotherapy in an office setting, as well as the financial ramifications of this investment in time and resources.
This webcast was recorded at a live event at ASCO SITC 2018. During this event, three leading experts challenged participants with quiz questions, which formed a basis for in-depth discussions supported by slide presentations. Participants were able to test and expand their knowledge on the increasingly important role of biomarkers in immuno-oncology. The experts examined the tumor microenvironment and addressed the evidence base for, and the future potential of, current and emerging biomarkers in guiding treatment decisions and in predicting the response to immuno-oncology therapeutics. Participants also learned about the role and importance of next-generation sequencing for the evaluation of novel immune biomarkers and for daily clinical practice.
RAISING THE BAR BY LOWERING THE TARGET Integrating PCSK9 Inhibitors into Hypercholesterolemia ManagementFormat: Resource Center
This CME-accredited CME Snapshot™ seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia.
During these quick-hitting activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin/kexin type 9 (PCSK9). Physicians can complete all 7 video modules for a total of 2.0 AMA PRA Category 1 Credits™.
This is a two-part CME activity with Part 1 highlighting real-world approaches to patient care utilizing design intelligent patients who have realistic and consistent human-to-human interaction and communication skills, opening possibilities for clinical psychosocial applications that address interviewing skills, diagnostic assessment and therapy training. The platform provides real-time feedback for continuous assessment and creates a personalized learning experience by presenting learners with data regarding their performance against peers. Part 2 of this activity is an Expert Exchange webcast that provides learners with a concise educational experience featuring two clinical experts exploring real-world approaches to patient care.
Biologic agents that revolutionized the treatment of patients with rheumatoid arthritis (RA) are now being reformulated as biosimilar agents. However, many questions remain regarding biosimilars: "What are they?", "Are they truly interchangeable with their reference biologics?", and "What are the clinical and financial implications of biosimilars in the treatment of patients with RA?" This archived symposium activity will provide participants with the opportunity to identify key differences between biosimilars and their reference biologics, review policy guidelines for biosimilars including naming and considerations for interchangeability, and assess data on the efficacy, safety, and clinical implications of biosimilars as part of RA patient management.
Welcome to Progress in Pleural Mesothelioma, an Elsevier Learning Center. The aim of this learning center is to increase clinical knowledge by providing continuing medical education (CME) activities, research articles, and resources for health care professionals (HCPs) who treat patients with pleural mesothelioma.
Biosimilars, which have been available in Europe for more than 10 years, are increasingly gaining regulatory approval in the United States. These agents have the potential to contain rapidly increasing health care costs and simultaneously enable greater patient access. The cornerstone of broad acceptance of biosimilars is increased education of all involved parties regarding regulatory standards for biosimilar approval, preclinical and clinical data requirements, interchangeability, and extrapolation of indications.
Dravet syndrome (DS), a rare form of epilepsy, occurs in approximately 1 in 20,000 live births and is associated with a significant humanistic and economic burden on caregivers, families, and patients. While many medications are used in treating the seizures associated with DS, there are currently no FDA-approved treatments, and nearly all patients continue to have uncontrolled seizures and other medical needs throughout their lifetime. Several investigational therapies are in late-stage development with the potential to provide new treatment options to address the serious medical needs for patients with DS.
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrotic lung disease of unknown cause. Early diagnosis is a prerequisite for earlier treatment and, potentially, improved long-term clinical outcomes. Familiarity with novel treatment approaches that hold the promise of slowing disease progression and with the recent guideline recommendations is essential for all clinicians involved in the care of patients with IPF. Individualizing treatment is important in light of potential improved adherence to both drug therapy and health behaviors.
ASCO & ESMO 2017 Highlights: Incorporating Immuno-oncology Agents into Solid and Liquid Tumor Treatment ParadigmsFormat: Webcast
The goal of this initiative is to help medical oncology and hematology-oncology physicians and advanced practitioners in community and academic settings to integrate checkpoint inhibitors into cancer treatment regimens and understand their unique safety and response profiles.
Join us to test and expand your knowledge on the increasingly important role of biomarkers in immuno-oncology. Three leading experts will challenge you with quiz questions that lay the basis for in-depth discussions supported by slide presentations. In this interactive learning experience we will examine the tumor microenvironment and address the evidence base and the future potential of current and emerging biomarkers in guiding treatment decisions and in predicting the response to immuno-oncology therapeutics. You will also learn about the role and importance of next-generation sequencing for the evaluation of novel immune biomarkers and for your daily clinical practice.
In the United States, as many as 2 million patients are annually diagnosed with antibiotic-resistant Gram-positive or Gram-negative (GP/GN) infections. Unfortunately, the development of novel antibiotics has lagged dangerously behind the emergence of resistant infections, leaving these patients with limited treatment options. Recently, several novel antibiotics have been approved, and more are in the clinical pipeline, many of which have proven to be particularly effective in patients with harder-to-treat GP and/or GN pathogens. However, in the absence of the judicious use of these new antibiotics, acquired resistance to these new agents is inevitable. This archived symposium will provide participants with the opportunity to review the clinical utility of new and investigational antimicrobials while also focusing on strategies to promote careful, appropriate antibiotic utilization. Interactive patient case scenarios will allow clinicians to apply acquired knowledge of antibiotic use to real-world examples of treating patients with GP/GN infections.
This webcast was recorded during a live symposium at the American Society of Human Genetics (ASHG) Annual Meeting in Orlando, FL, USA, on October 19, 2017. During the symposium, the faculty of leading KOLs in the field provided an overview of the clinical picture of Fabry disease and its natural history. They offered guidance on identifying the correlation between genotype and phenotype and how this may affect disease progression. They also discussed the current need for individualized patient care, and reviewed the emerging treatment landscape on the basis of the latest scientific data. They used interactive plenary sessions and selected patient case presentations to encourage the exchange of views and opinions on diagnosing and treating this disease.
MSPARIS2017: Clinical Updates on Disease Modifying Therapies to Improve Outcomes for Patients with Multiple SclerosisFormat: Medical Meeting Reporter
This educational activity will feature content presented at the MS Paris 2017 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. Four expert faculty will examine recent prognosis and diagnostic strategies of multiple sclerosis. An analysis of clinical trial data of current and emerging disease modifying therapies as presented at the Joint ACTRIMS-ECTRIMS meeting will be discussed. The faculty will also review how to implement recent scientific data to safely manage patients with multiple sclerosis for optimal outcomes. Upon completion of this activity, learners will gain a better understanding of recent clinical trial data for the treatment of multiple sclerosis, ultimately improving patient outcomes.
The 71st American Epilepsy Society (AES) Annual Meeting was held in Washington, DC, December 1-5, 2017. The conference attracts clinicians, scientists investigating basic and clinical aspects of epilepsy, and other professionals interested in seizure disorders. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on seizure disorders.
Community oncologists are challenged to stay up to date with updated clinical practice guidelines on the personalization of treatments for genitourinary (GU) cancers, including prostate, urothelial, and renal cancers, combination/sequential therapies, emerging safety and efficacy data from ongoing studies of novel regimens, and strategies to facilitate patient engagement in order to improve patient outcomes. Clinicians need tools and resources to help educate their patients and empower them to participate in their care and make educated treatment choices. Advanced-stage GU cancers consists of a spectrum of disease that requires an integrated multidisciplinary approach supported by a uro-oncologic team. Therefore, it is critical to educate these clinicians on their roles within the multidisciplinary cancer care team and on the importance of effective communication with other members of the team to maximize patient outcomes.
This CME program will feature content presented at the the 69th Annual American Academy of Neurology (AAN) Meeting held in Boston, Massachusetts. Three expert faculty will analyze recent therapeutic advances in the treatment and management of patients with multiple sclerosis. The clinical relevance of emerging and emerged trial data will be reviewed. Faculty will discuss strategies for utilizing the multidisciplinary team approach to develop and implement personalized treatment plans, accommodating patient-specific disease characteristics. Upon completion of the activity, learners will have a better grasp of evolving science in the field of multiple sclerosis as it relates to clinical practice.
Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of PCSK9 Inhibitor TherapeuticsFormat: Webcast
This educational content was derived from the American College of Physicians (ACP) Internal Medicine Meeting 2017 in San Diego, California. This activity will focus on optimized treatment plans for patients with dyslipidemia in the era of PCSK9 inhibitor therapeutics. LDL-C has been identified as an important therapeutic target to prevent the progression of atherosclerotic disease, however only 1 out of every 3 adults with high LDL-C has the condition under control. Expert faculty on this panel will discuss the science of PCSK9 inhibitors and aid physicians in the best practices to get their patients at LDL-C target.
Perspectives from the American Academy of Dermatology 2017 Meeting: Clinical Strategies and Scientific Advances in Atopic DermatitisFormat: Webcast
After many years of little movement in new therapies for patients with atopic dermatitis (AD), significant growth in researching the pathogenesis of AD has resulted in a better understanding of its causes, which has led to new protein targets for novel monoclonal antibodies (mABs). Often diagnosed in infancy, AD can persist into adulthood, affecting 3% to 5% of adults in the United States. Approximately 20% of children and adult patients have been diagnosed with moderate-to-severe AD. For this patient population, these latest advances continue to offer hope, as the current standard of care, which largely centers on symptom management, is suboptimal. This enduring video-based roundtable activity provides the latest updates on AD, including data on emerging and novel treatment options. Expert clinical faculty will also discuss the latest research on AD presented at the American Academy of Dermatology 2017 Annual Meeting.
Severe Asthma and the Primary Care Provider: Identifying Patients and Coordinating Multidisciplinary CareFormat: Webcast
This CME-accredited Through Your Patient’s EyesTM program is intended for primary care providers and other clinicians who manage patients with asthma. This educational activity has been designed to highlight issues faced by people living with asthma, including patients’ perspectives on the burdens of severe disease, difficulties related to suboptimal health literacy, and potential hurdles that can arise in busy healthcare practices. Specialist and primary care faculty discuss practical advice on overcoming these challenges, how to best coordinate multidisciplinary care, and actionable recommendations on identifying, comprehensively assessing, and longitudinally managing patients with severe asthma. As a result, clinician learners will be better prepared to engage and educate their patients with severe asthma, while improving long-term outcomes through personalized evidence-based care.
This article reviews the role of immunotherapy in the treatment of locally advanced and metastatic urothelial cell carcinoma (UC). It describes the basic principles of cancer immunotherapy, as they relate to management of UC, and summarizes clinical data on current and investigational therapeutic approaches. Two immune checkpoint inhibitors are now approved for treatment of advanced UC in the United States, and the article discusses their unique response patterns and side effect profiles to help oncology clinicians appropriately incorporate these agents into patient care.
An Update on Scientific Advances and Clinical Strategies in Chronic Obstructive Pulmonary Disease (COPD) from the ATS 2017 International ConferenceFormat: Conference Reporter
The 2017 American Thoracic Society (ATS) International Conference was held in Washington, DC, May 19–24, 2017. As a leading meeting in respiratory medicine, dedicated to advancing the clinical and scientific understanding of pulmonary diseases, critical illnesses, and sleep-related breathing disorders, the ATS Conference attracts thousands of participants from around the world. The 2017 ATS conference featured 6700 original research projects, 500 sessions, and 800 speakers. In this activity, 2 experts summarize the key learnings on COPD from this year’s conference.
The content for this activity is based on the CME Forum Focus on Uterine Fibroids: Evolving Options to Optimize Care that was presented at the 2017 ACOG Annual Clinical and Scientific Meeting in San Diego, California, on May 8, 2017.
Inflammatory bowel syndrome (IBS) is the most common gastrointestinal disorder seen by primary care providers, yet it remains a source of frustration for both patients and physicians. Recent advances in our understanding of the etiology and pathophysiology of IBS have led to new diagnostic guidelines that avoid unnecessary testing so that IBS is no longer a diagnosis of exclusion. Treatment options are varied and evolving and include pharmacologic and non-pharmacologic options depending on the subtype of IBS and individual patient characteristics. This archived symposium will provide participants with the opportunity to assess new data and remaining challenges in the diagnosis and treatment of patients with IBS via interactive case scenarios.
Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT, as well as with increased risk of secondary bacterial and fungal infections. Antiviral prophylaxis, more commonly used after SOT, is effective against direct and indirect effects of CMV infection, but may lead to overtreatment. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Several antiviral agents are currently available for CMV management; however, their use may be associated with myelosuppression and nephrotoxicity. Novel antiviral therapies with different mechanisms of action are in late-stage development and hold the promise of reducing CMV-related morbidity and mortality.
The 59th Annual Scientific Meeting of the American Headache Society (AHS) was held in Boston, Massachusetts, June 8 to June 11, 2017. The conference attracts medical professionals involved in the care of patients with head, neck, and orofacial pain. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on migraine.
This activity includes eight 30-minute modules that bring learners up to date on all aspects of cystic fibrosis (CF) treatment and management. Dr. John P. Clancy interviews eight experts in the CF field, each with their own specialization. The individual modules will focus on different areas of CF care, ranging from newborn screening to long-term real world efficacy and safety data. Each module is worth approximately 0.5 CME/CNE credits.
The Emerging Role of CFTR Combination Regimens in Improving Outcomes for Patients With Cystic FibrosisFormat: Live Meeting
This live, inter professional continuing education seminar will highlight the latest advances in CFTR-based therapeutics for the treatment of patients with cystic fibrosis. The expert faculty will utilize an interactive panel format to present and discuss recent trial data as it relates to clinical decision-making, including updates regarding the assessment, monitoring, and management of patients treated with CFTR modulated therapies. This educational activity is intended to increase the knowledge and competencies of the multidisciplinary team involved in the care of the CF patient population. Upon completion of this educational activity, the healthcare team will be better equipped with vital information for improving outcomes and quality of life in patients with cystic fibrosis.
This CME-accredited Clinical IssuesTM program is intended for allergists/clinical immunologists, pulmonologists, and other healthcare providers involved in the management of patients with severe asthma. During the activity, a panel of expert faculty discuss and debate a series of topics related to the evaluation and long-term treatment of various severe asthma phenotypes. Activity topics include classification of severe asthma, disease biomarkers, comorbidity management, and current and emerging targeted biologic therapies. The goal is to provide clinician learners with the latest evidence and a fresh perspective on evolving management paradigms for severe asthma.
THE ROLE OF PCSK9 INHIBITORS IN LOWERING LDL-C AND REDUCING CARDIOVASCULAR RISK IN PATIENTS WITH DYSLIPIDEMIAFormat: Conference Reporter
This CME program will feature content presented at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, Spain. Four expert faculty will analyze recent therapeutic advances in the treatment and management of patients with dylispidemia, as well as the role of PCSK9 inhibitors in lowering LDL-C and reducing cardiovascular risk in those patients. Long-term cardiovascular efficacy and safety data will be reviewed, and clinical relevance debated. Further, the expert faculty will outline strategies for utilizing the inter-professional team and incorporating recent data into individualized treatment plans. Upon completion of this CME activity, learners will have a better grasp of evolving science in the field of dyslipidemia as it relates to improving outcomes and quality of life in clinical practice.
Clinical Advances in Chronic Obstructive Pulmonary Disease: A Focus on Improving Patient Outcomes Learning CenterFormat: Resource Center
Welcome to Clinical Advances in Chronic Obstructive Pulmonary Disease: A Focus on Improving Patient Outcomes Learning Center. The Learning Center provides you with free access to the latest clinical information relating to the diagnosis and management of COPD. The COPD Learning Center is a freely accessible platform that aims to increase clinical knowledge by providing continuing medical educational (CME) activities, research articles and resources for healthcare providers who treat patients with COPD.
AAIC 2017: AN UPDATE ON SCIENTIFIC ADVANCES AND CLINICAL STRATEGIES IN ALZHEIMER’S DISEASE FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE®Format: Conference Reporter
The Alzheimer’s Association International Conference® 2017 (AAIC®) was held in London, England, July 16-20, 2017. As the largest international meeting dedicated to advancing dementia science, AAIC unites leaders from more than 70 countries to discuss the latest dementia study results and theories. In this activity, 2 experts summarize the key learnings from this year’s conference.
This webcast on relapsed/refractory acute lymphoblastic leukemia (R/R ALL) is based on a roundtable discussion by three experts, who provide an overview of challenges in the treatment of R/R ALL and summarize and discuss the latest data presented during the European Hematology Association (EHA) Annual Congress 2017, held on June 22–25 in Madrid, Spain. Progressing clinical trial outcomes of targeted therapies for R/R ALL, such as the anti-CD22 immunoconjugate inotuzumab ozogamicin, the anti-CD19 bi-specific T-cell engager (BiTE) blinatumomab, and CAR-T cell therapy will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with R/R ALL.
CONFRONTING THE CHALLENGE OF COPD: WHAT IS NEW IN THE APPROACHES TO DIAGNOSIS, TREATMENT, AND PATIENT OUTCOMESFormat: Webcast
Most aspects of chronic obstructive pulmonary disease (COPD) have been undergoing renewed scrutiny in recent years, with research investigating the entire spectrum of disease development and progression, the genetic phenotypes and risk factors, disease heterogeneity, refinements in diagnostic approaches, advances in treatment options, and so forth. This activity provides insights into new approaches to identifying patients with undiagnosed COPD, the importance of early initiation of pharmacologic treatment in a guideline-congruent manner, and the importance of repeated patient training in correct inhaler technique in order to improve adherence and patient outcomes.
AN UPDATE ON SCIENTIFIC ADVANCES AND CLINICAL STRATEGIES IN MIGRAINE AND OTHER PRIMARY HEADACHE DISORDERSFormat: Conference Reporter
The 18th Congress of the International Headache Society (IHC) was held in Vancouver, BC, Canada, September 7 to 10, 2017. The conference attracts medical professionals involved in the care of patients with new developments in the advancement of headache science, education, and management. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on migraine.
This activity is presented as a roundtable discussion between three international expert faculty in cystic fibrosis (CF). This expert faculty will discuss the role of aerosolized agents for improving airway clearance, including caveats from their own extensive clinical experience in managing patients with this condition. The faculty will also deliberate on strategies to improve patient adherence to CF therapy in a case study based format. These discussions will support participants in clinical decision making as well as in helping their patients achieve optimal benefit through adherence to their CF therapy.
This webcast on metastatic renal cell carcinoma (mRCC) is based on a roundtable discussion among three key opinion leaders in the field. The experts will present updates on the management of mRCC and summarize and discuss the latest clinical trial data presented during the ESMO 2017 Congress, held in Madrid, Spain, on September 8–12, 2017. Advances in the use of targeted therapies such as VEGFR inhibitors, novel immunotherapies, and combination therapies including PD-1/PD-L1 and CTLA4 targeting agents will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with mRCC.
This webcast on gastric cancer (GC) is based on a roundtable discussion among three key opinion leaders in the field. The experts will present updates on the management of GC and summarize and discuss the latest clinical trial data presented during the ESMO 2017 Congress, held in Madrid, Spain, and the 2017 ASCO Annual Meeting, held in Chicago, USA. Advances in perioperative treatment strategies, targeted therapies such as HER2 inhibitors, and novel immunotherapies including agents targeting PD-1/PD-L1 will be examined. The experts will address the question of how novel treatment options, when approved, could be included in individualized treatment plans, to optimize treatment selection and outcomes for patients with GC.
ESMO 2017: A Therapeutic Update on the Management of Patients with Advanced Hepatocellular CarcinomaFormat: Medical Meeting Reporter
This webcast on hepatocellular carcinoma (HCC) is based on a presentation by an expert, who provides an overview of the advances in the management of HCC and summarizes and discusses the latest data presented during the European Society for Medical Oncology (ESMO) Annual Meeting 2017, held on September 8-12 in Madrid, Spain. Results of clinical trials of targeted therapies that have been evaluated in first-line and second-line setting in advanced HCC and their possible effect on treatment guidelines will be examined. Additionally, the potential role of biomarkers as prognostic factors of response to targeted therapies, particularly in clinical practice, will also be discussed. The expert will also discuss the most promising new agents in advanced clinical trials in HCC and how they might impact the treatment landscape in HCC.
The European Respiratory Society (ERS) International Congress 2017 was held in Milan, Italy, September 9-13, 2017. The Congress has been a platform for improving standards in respiratory medicine and putting the spotlight on respiratory care. In this activity, 2 experts summarize the key learnings from this year’s Congress focusing on Idiopathic Pulmonary Fibrosis (IPF).
Migraine treatment includes both preventive therapy, aimed at reducing attack frequency and severity, and acute therapy, for aborting attacks. For acute therapy, the most widely used drugs are NSAIDs and triptans. Routes of triptan administration include oral, intranasal, suppository, subcutaneous, and transdermal iontophoretic, as well as a variety of device-enhanced delivery options. Relatively slow onset of action remains a limitation for these formulations, except for the injectable delivery. Novel routes of delivery, such as intradermal, are in development, holding the promise of rapid absorption into the systemic circulation and, thus, rapid relief. Ultimately, the abundance of delivery options provides more choices to patients with migraine.
These virtual patient panels provide learners with real-world application of best practices among various members of the healthcare team in the management of patients with hyponatremia. A patient case is provided, followed by discussion among the team members to provide insight and context to why particular courses of action were chosen.
The CHEST Annual Meeting 2017 was held in Toronto, Ontario, Canada, October 28–November 1, 2017. As the premier chest medicine education meeting for clinicians, CHEST unites leaders to discuss current pulmonary, critical care, and sleep medicine topics. In this activity, 2 experts summarize the key learnings from this year’s Annual Meeting, focusing on chronic obstructive pulmonary disease (COPD).
Metastatic melanoma has a high mortality rate and is refractory to traditional treatments, but recent clinical trials have shown significantly improved patient outcomes with checkpoint inhibitors. However, treating physicians may find its use challenging due to limited clinical experience and confidence in prescribing immunotherapies, especially among patient populations under-represented in clinical trials and in managing immune-related adverse events. This webinar will cover the current practices and challenges in management of metastatic melanoma, as well as insights on the future management of melanoma patients.
Incorporating Immuno-oncology Agents into Solid and Liquid Tumor Treatment Paradigms: Highlights from ASCO 2017 – Expert DiscussionFormat: Webcast
Immunotherapy is now an established treatment approach for patients with cancer across oncology. Immunotherapy agents are a newer type of anticancer drug, and the drugs in the largest class, checkpoint inhibitors, block the checkpoint pathways that cancer cells use to shut down the patient’s immune system. Checkpoint inhibitors are associated with more durable clinical responses compared to both small molecule targeted therapy and conventional chemotherapy (CT). Because checkpoint inhibitors have unique mechanisms of action, they also produce immune-related adverse events and response patterns that are markedly distinct from targeted agents or conventional CT. The 5 currently available immunotherapy agents have 18 indications across multiple cancer types. Checkpoint inhibitors demonstrate the potential to change current cancer treatment paradigms.
In this interactive CE activity, a leading medical oncologist discusses highlights of several key presentations from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting on the use of checkpoint inhibitors in several cancer types. Topics include questions on appropriate clinical setting for immunotherapy (eg, refractory cancer), dose, combination therapy, treatment beyond progression, and side-effect profile for patients.
The Global Learning Center provides you with free access to the latest peer-reviewed clinical information relating to the treatment of psoriatic arthritis. The Psoriatic Arthritis Global Learning Center is a freely accessible platform that aims to increase clinical knowledge by providing continuing medical educational activities, research articles and resources for healthcare providers who treat patients with psoriatic arthritis.
AN UPDATE ON EMERGING S1P THERAPEUTICS FOR THE MANAGEMENT OF PATIENTS WITH RELAPSING MULTIPLE SCLEROSISFormat: Conference Reporter
This CME program will highlight data presented at the 7th Annual Joint ECTRIMS – ACTRIMS Meeting in Paris, France. The three expert faculty will analyze recent therapeutic advances in the treatment and management of multiple sclerosis (MS). The clinical relevance of emerging and emerged trial data, particularly regarding S1P therapeutics, will be assessed. Faculty will outline strategies for utilizing the multidisciplinary team approach to develop and implement data-driven, tailored treatment plans in clinical practice. Upon completion of this CME activity, learners will have a better grasp of evolving science in the field of MS in order to improve outcomes and quality of care.
The content for this activity is derived from a live symposium titled, “Applying PCSK9 Inhibitors to Optimize Outcomes in Patients With Dyslipidemia” presented at the American Heart Association Scientific Sessions 2017 in Anaheim, California. This CME activity will highlight optimal treatment and management strategies for patients with dyslipidemia in the era of PCSK9 inhibitors. The expert faculty will review recent clinical trial and CVD outcomes data, encompassing lipid lowering therapies for the diabetic patient subset. Dyslipidemia guidelines as well as strategies for achieving LDL-C goal will be outlined, particularly in the high-risk population. Dr. Christopher P. Cannon and the accompanying faculty will utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision making. This CME program will provide cardiologists with vital information for improving healthcare outcomes in patients with dyslipidemia.
This webcast was recorded during a satellite symposium at the 46th Child Neurology Society (CNS) Annual Meeting in Kansas, MO, USA, on October 6, 2017. During the symposium, the faculty of leading KOLs in the field provided an overview of the genetics and biology of spinal muscular atrophy (SMA) and addressed the subject of the importance of early diagnosis and accurate classification. The use of gene profiling and a review of the current best practices in multidisciplinary management were included in the program, and were illustrated with selected patient case presentations. The panel of experts discussed unmet needs in SMA management, and examined emerging treatment options based on the latest scientific data; they used plenary presentations to encourage the exchange of views and opinions on the rapidly evolving SMA treatment landscape.
AHA 2017: APPLYING PCSK9 INHIBITORS TO IMPROVE OUTCOMES AND THE OVERALL QUALITY OF LIFE FOR PATIENTS WITH DYSLIPIDEMIAFormat: Conference Reporter
This Elsevier Conference Reporter will cover data presented at the American Heart Association (AHA) Scientific Session 2017 held in Anaheim, CA. The expert faculty will discuss the role of PCSK9 inhibitors for the treatment of dyslipidemia including achieving LDL-C goals, cardiovascular risk reduction and managing special patient populations. Current and emerging clinical trial data of PCSK9 inhibitors will be analyzed. The faculty will discuss different approaches of how to implement newer therapies into individualized treatment plans. Upon completing this activity, clinicians will gain a better understanding of treatment options to provide better outcomes for patients with dyslipidemia.
THE EMERGING ROLE OF CFTR COMBINATION REGIMENS IN IMPROVING OUTCOMES FOR PATIENTS WITH CYSTIC FIBROSISFormat: Webcast
The content for this activity is based on the live, inter professional seminar titled, “The Emerging Role of CFTR Combination Regimens in Improving Outcomes for Patients With Cystic Fibrosis” that was presented at the 31st Annual North American Cystic Fibrosis Conference in Indianapolis, Indiana. This CME/CNE activity will highlight the latest advances in CFTR-based therapeutics for the treatment of patients with cystic fibrosis. The expert faculty will utilize an interactive panel format to present and discuss recent trial data as it relates to clinical decision-making, including updates regarding the assessment, monitoring, and management of patients treated with CFTR modulated therapies. This educational activity is intended to increase the knowledge and competencies of the multidisciplinary team involved in the care of the CF patient population. Upon completion of this educational activity, the healthcare team will be better equipped with vital information for improving outcomes and quality of life in patients with cystic fibrosis.
This symposium will bring together experts from around the world to engage in a lively in-depth discussion on the key clinical questions and controversies in the diagnosis of lysosomal storage diseases (LSDs) and the future direction of LSD management. This program will address the consequences of delayed diagnosis and treatment initiation, and help you better understand diagnostic options. The experts will discuss genotype–phenotype correlations and their significance for daily clinical practice, and provide perspectives on emerging therapeutic developments and strategies for the treatment of LSDs.
Looking Beneath the Surface in Atopic Dermatitis: Targeting Immune Dysregulation and Delivering Comprehensive CareFormat: Webcast
This Interactive Exchange™ program will open with a brief 3D-animated video focused on the pathophysiologic underpinnings of atopic dermatitis. Expert faculty will then discuss best practices for comprehensive patient evaluations and the clinical profiles of systemic treatment options for patients with moderate-to-severe disease. With an overall goal of improving patient outcomes, this educational session has been designed to allow internationally recognized experts to translate the latest published evidence into actionable recommendations for individualized patient care.
Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and TreatmentFormat: Webcast
The content for this activity is based on the satellite symposium Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment that was presented on October 24, 2016 in Los Angeles, CA. Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrotic lung disease of unknown cause. Early diagnosis is a prerequisite for earlier treatment and, potentially, improved long-term clinical outcomes. Familiarity with novel treatment approaches that hold the promise of slowing disease progression and with the recent guideline recommendations is essential for all clinicians involved in the care of patients with IPF. Individualizing treatment is important in light of potential improved adherence to both drug therapy and health behaviors.
Perspectives from the American Academy of Dermatology 2017 Meeting: Clinical Strategies and Scientific Advances in Atopic DermatitisFormat: Webcast
After many years of little movement in new therapies for patients with atopic dermatitis (AD), significant growth in researching the pathogenesis of AD has resulted in a better understanding of its causes, which has led to new protein targets for novel monoclonal antibodies (mABs). Often diagnosed in infancy, AD can persist into adulthood, affecting 3% to 5% of adults in the United States. Approximately 20% of children and adult patients have been diagnosed with moderate-to-severe AD. For this patient population, these latest advances continue to offer hope, as the current standard of care, which largely centers on symptom management, is suboptimal. This enduring video-based roundtable activity provides the latest updates on AD, including data on emerging and novel treatment options. Expert clinical faculty will also discuss the latest research in AD presented at the 41st Annual Hawaii Dermatology Seminar.
Neuromuscular blocking agents (NMBAs) are used in many surgical procedures and have enabled new surgical advances. The expanded landscape of NMB reversal drugs allows for fast and complete neuromuscular blockade (NMB) reversal and the reduction of postoperative complications from residual block. In the United States, neostigmine/ glycopyrrolate and sugammadex are the primary agents for pharmacologic antagonism of NMBAs. While neostigmine and an anticholinergic have been available for decades, sugammadex has only recently become available. We present real-world cases in a variety of surgeries and clinical settings in which the use of NMB reversal agents played a significant role in the patients clinical outcome.
Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with TolerabilityFormat: Webcast
Effective treatment of major depressive disorder with antidepressants is currently limited by factors that affect treatment compliance, including delay in onset of therapeutic effects and, often, intolerable side-effects. Recent data suggest that use of antidepressant combinations with different mechanisms of action may be a better first-line strategy prior to augmentation with other drug classes. The rationale for this approach is that combining multiple pharmacological actions affecting multiple monoamine targets produces greater efficacy. The latest data on multimodal therapies indicate shorter onset of therapeutic effects and improved tolerability. By modulating multiple receptors and neurotransmitter systems, it is hoped that these new agents may also treat some of the associated symptoms of major depressive disorder, such as anxiety and cognitive dysfunction.
The Global Learning Center provides you with free access to the latest peer-reviewed clinical information related to the treatment of patients with rheumatoid arthritis (RA). The RA Global Learning Center is a freely accessible platform that aims to increase clinical knowledge by providing continuing medical educational (CME) activities, research articles, and other resources to healthcare providers who treat patients with RA.
This symposium archive will provide participants with the opportunity to assess remaining challenges in the care of patients with spasticity. In addition to reviewing appropriate use of chemodenervation and other treatments, this activity will also highlight techniques for improved communication between physicians and patients regarding the causes of functional impairments, individualized treatment options, customized goals of treatment, and the need for post-intervention rehabilitation and home programs via interactive video case presentations.
The content for this activity is based on the satellite symposium, Spasticity Video Challenge: A Look at Methods for Addressing Difficult Cases, that was presented at the AAPM&R Annual Assembly in New Orleans, Louisiana on October 22, 2016.
This activity will focus on the most current clinical trial data for achieving LDL-C goal for all patients in the era of PCSK9 inhibitors as presented as an Unofficial Satellite Event at the American Heart Association Scientific Sessions 2016. The expert faculty utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision-making. The educational material of this symposium will provide information that every cardiologists needs to know to improve healthcare outcomes in their patients with cardiovascular disease.
This CME activity will focus on the management of patients with familial hypercholesterolemia and the role of PCSK9 inhibitors in this therapeutic area. Expert faculty will review the science of PCSK9, the updated standards of care for the diagnosis, and FH scoring and management of patients with familial hypercholesterolemia. Clinical trial data of PCSK9 inhibitors for the treatment of familial hypercholesterolemia, including long-term efficacy and safety data, will be analyzed. The faculty will guide physicians on how to implement a multidisciplinary approach to optimally manage patient-specific disease to improve outcomes for patients with familial hypercholesterolemia. Upon completing this activity, physicians will gain knowledge on the most up-to-date care for this cohort of patients.